KALA, Petr, Petr OSTADAL, Zuzana MOT'OVSKA, Martin MATES, Dagmar VONDRAKOVA, Jan BELOHLAVEK, Petr FILA and Ivo VARVAROVSKY. Doporučení ESC pro léčbu akutních koronárních syndromů 2023 (ESC recommendations for the treatment of acute coronary syndromes 2023). cor et Vasa. PRAGUE 2: CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERY, 2024, vol. 66, No 2, p. 169-232. ISSN 0010-8650. Available from: https://dx.doi.org/10.33678/cor.2024.029.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Doporučení ESC pro léčbu akutních koronárních syndromů 2023
Name (in English) ESC recommendations for the treatment of acute coronary syndromes 2023
Authors KALA, Petr (203 Czech Republic, belonging to the institution), Petr OSTADAL (203 Czech Republic), Zuzana MOT'OVSKA (203 Czech Republic), Martin MATES (203 Czech Republic), Dagmar VONDRAKOVA (203 Czech Republic), Jan BELOHLAVEK (203 Czech Republic), Petr FILA (203 Czech Republic) and Ivo VARVAROVSKY (203 Czech Republic).
Edition cor et Vasa, PRAGUE 2, CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERY, 2024, 0010-8650.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 0.200 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.33678/cor.2024.029
UT WoS 001232161500001
Keywords in English acute cardiac care; acute coronary syndrome
Tags 14110211, rivok
Tags Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 22/8/2024 10:59.
Abstract
Doporučené postupy hodnotí a shrnují dostupné důkazy s cílem pomoci zdravotnickým profesionálům a nevylučují individuální odpovědnost zdravotníků. Off-label použití léků může být uvedeno v případě dostatečné úrovně důkazů.
Abstract (in English)
The recommended practices assess and summarise the available evidence to assist health professionals and do not exclude individual responsibility of health professionals. Off-label use of medications may be indicated if the level of evidence is sufficient.
PrintDisplayed: 25/8/2024 15:20